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Proteolysis is essential during branching morpho-
genesis, but the roles of MT-MMPs and their proteo-
lytic products are not clearly understood. Here, we
discover that decreasing MT-MMP activity during
submandibular gland branching morphogenesis
decreases proliferation and increases collagen IV
and MT-MMP expression. Specifically, reducing
epithelialMT2-MMP profoundly decreases prolifera-
tion andmorphogenesis, increasesCol4a2 and intra-
cellular accumulation of collagen IV, and decreases
the proteolytic release of collagen IV NC1 domains.
Importantly, we demonstrate the presence of
collagen IV NC1 domains in developing tissue.
Furthermore, recombinant collagen IV NC1 domains
rescue branching morphogenesis after MT2-siRNA
treatment, increasing MT-MMP and proproliferative
gene expression via b1 integrin and PI3K-AKT
signaling. Additionally, HBEGF also rescues MT2-
siRNA treatment, increasing NC1 domain release,
proliferation, and MT2-MMP and Hbegf expression.
Our studies provide mechanistic insight into how
MT2-MMP-dependent release of bioactive NC1
domains from collagen IV is critical for integrating
collagen IV synthesis and proteolysis with epithelial
proliferation during branching morphogenesis.
INTRODUCTION
Membrane-type matrix metalloproteinases (MT-MMPs) are
pericellular collagenolytic enzymes responsible for extracellular
matrix degradation in many biological processes (Holmbeck
et al., 1999; Hotary et al., 2000; Page-McCaw et al., 2007; Stern-
licht and Werb, 2001). During branching morphogenesis, cells
migrate into the stroma as an epithelial sheet, and both epithelia
and stroma produce basement membrane (BM) components
as well as proteases that degrade the BM (Bernfield et al.,
1984; Hogan, 1999; Lu and Werb, 2008; Metzger and Krasnow,482 Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsev1999). In contrast, during cancer cell invasion, invadopodia
perforate the intactBM,andcellular transmigrationoccurs (Artym
et al., 2006; Hotary et al., 2006). However, both branching
morphogenesis and cancer cell invasion require MT-MMPs to
degrade BM components, generating cleavage products with
potential signaling functions and locally releasing growth factors
stored in the BM (Ortega and Werb, 2002).
Most single MMP knockouts have subtle developmental
phenotypes, which have been explained because of enzymatic
redundancy, compensation, and adaptive development (Page-
McCaw et al., 2007). However, mice lacking MT1-MMP
(Mmp14/) have severely impaired collagen metabolism and
bone morphogenesis (Holmbeck et al., 1999; Zhou et al.,
2000), lung defects (Atkinson et al., 2005), and decreased
embryonic submandibular gland (SMG) branching morphogen-
esis (Oblander et al., 2005). MT1/MT3-MMP double null mice
die at birth with skeletal and craniofacial defects (Shi et al.,
2008). TheMMP2/MT1-MMP double null mice also die after birth
with respiratory failure and blood vessel and muscle defects
(Oh et al., 2004). However, transcriptional compensation among
different MMPs has not been reported in any of these knockout
mice.
MT-MMPs (referred to as MT1, MT2, and MT3) have overlap-
ping functions and target common substrates, but the differential
localization within specific tissues may specify their functions
(Page-McCaw et al., 2007; Szabova et al., 2005). MT-MMPs
regulate invasion of 3D collagen matrices by MDCK cells, and
cancer cell lines overexpressing MT1, MT2, or MT3, but not
MMP2 or MMP9, degrade and transmigrate collagen IV-contain-
ing ex vivo peritoneal BMs (Hotary et al., 2000, 2006). However,
multiple secreted and membrane-type MMPs can degrade
collagen IV in other biological contexts (Page-McCaw et al.,
2007). MT2 is also expressed in mammary epithelium (Szabova
et al., 2005); however, its role during branching morphogenesis
had not been investigated.
Collagen IV is essential for mouse development, providing
structural integrity to the BM, but is not required for deposition
or assembly of the BM (Poschl et al., 2004). It is ubiquitously ex-
pressed in branching organs (Kuhn, 1995; Poschl et al., 2004) as
a triple helix containing a 2:1 ratio of col4a1 and col4a2 chains
(Borza et al., 2001; Khoshnoodi et al., 2008; Vanacore et al.,
2004). MMP-mediated proteolysis of the native triple helix ofier Inc.
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MT2-MMP and Collagen-IV in SMG Morphogenesiscollagen IV releases NC1 domains, and although NC1 domains
have not been previously isolated from developing tissue, the
recombinant NC1 domains have distinct signaling properties
(Mundel and Kalluri, 2007; Sternlicht and Werb, 2001). The
capacity of exogenous NC1 domains to block tissue develop-
ment in vivo was first described in hydra (Zhang et al., 1994).
Recombinant a1(IV)NC1 and a2(IV)NC1 are antiangiogenic
(Petitclerc et al., 2000; Roth et al., 2005) and bind b1-containing
integrins (Khoshnoodi et al., 2008), but whether they regulate
MT-MMP expression and epithelial proliferation during branch-
ing morphogenesis is unknown.
SMG branching morphogenesis requires epithelial prolifera-
tion, end bud expansion, and cleft formation and is dependent
on local accumulation of extracellular matrix (Patel et al.,
2006). Cleft formation involves accumulation and turnover of
interstitial collagen fibers (Fukuda et al., 1988; Hayakawa et al.,
1992), and fibrillar collagens I and III are substrates for MT1
and MT3 (d’Ortho et al., 1997). More recently, important roles
for the accumulation and localization of other ECM components
in epithelial clefts, such as laminins, fibronectin, and perlecan,
have been reported (Patel et al., 2007; Rebustini et al., 2007;
Sakai et al., 2003). Nonetheless, the role of collagen IV synthesis
and proteolysis and the MT-MMPs involved during branching
morphogenesis are still unknown.
Here,we investigateMT2-dependent proteolysis of collagen IV
during branching morphogenesis. Knockdown of MT2 in explant
culture reduces cell proliferation and morphogenesis and
disrupts collagen IV metabolism, resulting in intracellular accu-
mulation of collagen IV and reduced production of NC1 domains.
We propose that the proteolytic release of NC1 domains plays
a critical role in branching morphogenesis by regulating further
protease expression and epithelial proliferation.
RESULTS
An MMP-Inhibitor and TIMP2 Decrease Branching
Morphogenesis and Epithelial Proliferation
and Increase Collagen IV Expression
A broad MMP inhibitor (GM6001) inhibits E13 SMG branching,
resulting in enlarged end buds, decreased epithelial cell prolifer-
ation, a striking accumulation of collagen IV, and reduced end
bud number (Figure 1A, insert graph in Figure 1B). The collagen
IV accumulation is around both epithelium and mesenchyme,
but themesenchymal accumulation ismost apparent in the single
projectionof a confocal stack of images (Figure 1A).GM6001also
increased Col4a2 8-fold and Col4a1 2-fold, whereas Lama5,
Hspg2, MT1, MT2, and MT3 did not change (Figure 1B). Gelatin
zymography of the conditioned medium showed that GM6001
inhibited secreted MMP2 activation in a time-dependent manner
(see Figure S1A available online). We also compared the effects
of exogenous TIMP1 with TIMP2, which inhibits both secreted
and MT1-, 2-, and 3-MMPs. TIMP2 but not TIMP1 significantly
decreased E13 SMG branching (Figure 1C). In addition, the
expression ofMT2,MT3, andCol4a2 increased after TIMP2 inhi-
bition (Figure 1C). Taken together, our results highlight the central
role of membrane-type, rather than secretedMMPs, during SMG
morphogenesis. This suggests that a proteolytic product of
MT-MMPsmay regulate epithelial proliferation and result in tran-
scriptional feedback to MT-MMP and collagen IV expression.DevelopMT2 Is Upregulated in MT1-Deficient SMGs
and during SMG Development When
Branching Morphogenesis Begins
The SMGs ofMT1/mice undergo reduced branchingmorpho-
genesis in culture, but branching of the lungs was not altered
(Oblander et al., 2005), suggesting that MT-MMPs may have
specific functions in the SMG. Transcriptional compensation
by other MT-MMPs was not reported; therefore, tissue-specific
differences in MT-MMP function may also occur. When we
cultured MT1+/+, MT1+/, and MT1/ SMGs, we confirmed
that there was decreased branching in MT1/ SMGs and also
discovered there was reduced branching in MT1+/ compared
to MT1+/+ SMGs (Figure 1D, pictures and insert graph). Func-
tion-blocking antibodies to MT1-MMP also reduced SMG
branching (Figure S1B). We confirmed the reduction and the
absence of MT1 expression in the MT1+/ and MT1/ SMGs,
respectively. However, we unexpectedly detected a specific
increase of MT2 in both MT1+/ (6.4-fold) and MT1/
(8.2-fold), compared to MT1+/+ SMGs. (Figure 1D). The data
suggest that a transcriptional compensation of MT2 expression
occurs with reduced MT1 expression in vivo, and since exoge-
nous TIMP2also increasedMT2 andMT3 expression (Figure 1C),
we investigated the spatiotemporal expression of the MT-MMPs
during SMG development.
We analyzed the expression of MT-MMPs and collagen IV
throughout SMG development. MT1, MT2, MT3, Mmps2, -9,
and -11, Col4a1, and Col4a2 were upregulated at E13, and
Mmps19 and -23 were also present (Figure 2A and Figure S2).
We separated E13 epithelium from the mesenchyme and
analyzed MMP expression by qPCR. MT2 was more abundant
in the epithelium, with MT1 and MT3 more abundant in the
mesenchyme (Figure 2B). Whole-mount immunofluorescent
analysis confirmed the predominant epithelial localization of
MT2, whereas MT3 was present in both epithelium and mesen-
chyme, and MT1 accumulated in the mesenchyme around cleft
regions of the epithelium (Figure 2C). The specificity of the
MT-MMP antibodies was confirmed using MT1/ and MT3/
SMGs or by using the immunizing peptide to compete the MT2
antibody (Figures S3A–S3C).
MT2-siRNA Decreases Branching Morphogenesis
and Increases Col4a2 Expression
The compensatory increases in MT-MMP expression (Figures 1
and 2) were further investigated using siRNAs to downregulate
MT1, MT2, and MT3 in SMG explant cultures. MT1-siRNA
decreased branching (Figure 3A), with a phenotype similar to the
MT1+/ and MT1/ SMGs (Figure 1D). Intriguingly, MT2-siRNA
resulted in the most severe disruption of branching: the end
buds enlarged but did not completely form clefts, and secondary
duct formation was delayed (Figure 3A). In contrast, MT3-siRNA
did not affect branching, and the SMGs appeared similar to
NS-siRNA treatment. All siRNA treatments decreased the
expression of their corresponding targeted mRNA and protein
by 50%, as measured by qPCR (Figure 3B) and whole-mount
immunostaining, respectively (Figure S3D). MT2-siRNA treat-
ment resulted in a 4.5-fold increase in Col4a2 and a 2.2-fold
increase in Lama5; MT1-siRNA and MT3-siRNA treatments
resulted in a 1.8-fold and a 6.2-fold increase inMT2 expression,
respectively. There was less transcriptional increase of MT2mental Cell 17, 482–493, October 20, 2009 ª2009 Elsevier Inc. 483
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MT2-MMP and Collagen-IV in SMG MorphogenesisFigure 1. Reducing MT-MMP Function Decreases SMG Morphogenesis and Proliferation, Increases Collagen IV Expression, and Upregu-
lates other MT-MMPs
(A) SMGs (E13) treated with GM6001, a broad MMP inhibitor, undergo less branching morphogenesis, proliferation decreases (Ki67 staining), and collagen IV
immunostaining increases. The whole-mount immunostaining is shown as a projection of an LSM stack.
(B) qPCR analysis shows Col4a2 increases8-fold and Col4a1 increases2-fold after GM6001 treatment. The insert graph shows the number of end buds with
GM6001 treatment expressed as a ratio of the number of end buds at T36/T0 hr.
(C) Exogenous TIMP2, an inhibitor of MT-MMPs, but not TIMP1 decreases the number of end buds and increasesMT2,MT3, andCol4a2 expression compared to
TIMP1 treatment.
(D)MT1/ andMT1+/ SMGs undergo less branching morphogenesis than MT1+/+, which is quantified in the insert graph, and there is a specific 7- to 8-fold
increase inMT2 expression by qPCR, while other MMPs and BM components do not change. Student’s t test for (A)–(C) and one-way ANOVA for (D), *p < 0.05,
**p < 0.01, and ***p < 0.001. Error bars represent ± SD.with MT1-siRNA (Figure 3B) compared to MT1+/ SMGs (Fig-
ure 1D), most likely because the genetic reduction in MT1+/
SMGs occurs earlier in development, whereas the knockdown484 Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevin explant culture occurs with existing proteolytic products
present. Additionally, the decrease in branching morphogenesis
with MT2-siRNA treatment was rescued by exogenousier Inc.
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MT2-MMP and Collagen-IV in SMG MorphogenesisFigure 2. MT2-MMP Is Predominantly Expressed in the SMG Epithelium and Increases When Branching Morphogenesis Begins
(A) qPCR analysis of SMG gene expression at distinct developmental stages shows that MT1, MT2, and MT3 increase at E13 when branching morphogenesis
begins.
(B) qPCR analysis of separated E13 SMG epithelium andmesenchyme shows thatMT2 is predominant in the epithelium, whereasMT1 andMT3 are predominant
in the mesenchyme. Error bars represent ± SD.
(C) Immunofluorescent analysis of MT-MMPs in E13 SMGs is in agreement with the qPCR data and shows that MT1 accumulates in the mesenchyme around the
end buds and in the clefts, MT2 is localized throughout the epithelium, and MT3 is in both tissues. Perlecan, a BM marker (green), and Topro3, a nuclear stain
(blue), are shown. M, mesenchyme; E, epithelium. Scale bar = 50 mM.recombinant MT2- and MT3-MMP catalytic domains (recMT2
and recMT3) but not recMT1 (Figure S4A). The recMTs are func-
tional in vitro, and we treated both SMG collagen IV and bovine
lensbasementmembranewith the recMTsandshow they release
NC1 domains (Figures S4D and S4E).
We also decreased MT-MMP expression directly in isolated
SMG epithelia cultured in a 3D laminin-111 ECM with FGF10
(Steinberg et al., 2005). MT2-siRNA had the greatest effect on
epithelial morphogenesis; MT1- (which is not highly expressed
in the epithelium) and MT3-siRNA did not decrease epithelial
morphogenesis and were similar to the NS-siRNA control (Fig-
ure 3C). Epithelial morphogenesis was expressed as a morpho-
genic index (number of end buds 3 duct length, in AU 3103),
which was significantly decreased with MT2-siRNA (Figure 3C,
graph). Analysis of gene expression in the MT2-siRNA-treated
epithelia showed a significant decrease of MT2 expression andDevelopa 3-fold increase of Col4a2 expression (Figure 3D). Epithelial
morphogenesis with MT2-siRNA was also rescued by recMT2
(Figure S4B). The ability of recMT2 to activate pro-MMP2 was
confirmed by gelatin zymography of the culture media after
siRNA and recMT2 treatment (Figure S4C). Taken together,
these experiments indicate that there is a coordinated transcrip-
tional regulation of MT-MMPs: reducingMT1 orMT3 expression
upregulates MT2, while reducing MT2 expression upregulates
MT3 expression. In addition, MT2-siRNA has the greatest effect
on SMG epithelial morphogenesis and specifically increases
Col4a2 expression.
MT2-siRNA Decreases Epithelial Cell Proliferation
and Increases Intracellular Collagen IV
We measured cell proliferation by Ki67 staining and immunolo-
calized collagen IV after MT-siRNA treatment. MT2-siRNAmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevier Inc. 485
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MT2-MMP and Collagen-IV in SMG MorphogenesisFigure 3. MT2-siRNA Decreases Epithelial
Morphogenesis in Both Intact SMGs and in
Isolated Epithelial Culture and Increases
Col4a2 Expression
(A) SMGs were cultured for 36 hr with nonsilencing
(NS) and MT1-, MT2-, and MT3-siRNAs. MT2-
siRNA has the most significant effect on epithelial
morphogenesis.
(B) The expression of MMPs and basement
membrane components were measured by
qPCR after siRNA treatment and normalized to
the expression with the NS-siRNA. MT1-siRNA
increases MT2 1.8-fold compared to control;
MT2-siRNA increases Col4a2 4-fold and MT3 1.5
fold; and MT3-siRNA increases MT2 6.2-fold and
MMP8 and 11 2-fold.
(C) Isolated SMG epithelia were cultured for 36 hr
with siRNAs. MT2- but not MT1- or MT3-siRNA
decreases epithelial morphogenesis compared
to NS-siRNA treatment. The Morphogenic Index
is the number of end buds 3 duct length, in
AU 3 103.
(D) qPCR analysis of the isolated epithelium shows
MT2-siRNA treatment significantly decreases
MT2 but increases Col4a2 3-fold. One-way
ANOVA for (A) and (C), Student’s t test for (B)
and (D); *p < 0.05; **p < 0.01, and ***p < 0.001.
Error bars represent ± SD.significantly decreased epithelial cell proliferation, particularly in
the end buds (Figure 4A, left panels), whereas NS-, MT1-, and
MT3-siRNAs had minimal effects on proliferation (Figure 4B).
We observed increased intracellular collagen IV, which was
most apparent in the epithelial cells in MT2-siRNA-treated
SMGs (Figure 4A, middle panels) as compared to MT1- and
MT3-siRNA treatments. The intracellular location was evident
when stacks of confocal sections stained with an epithelial cell
surface marker, syndecan 4, were analyzed (Figure S5A).
Staining with lamp1, a lysosomal marker, showed there was
not increased localization of the intracellular collagen IV in lyso-
somes (Figure S5B). Quantification of collagen IV staining shows
that while MT2-siRNA has the greatest effect, all MT-siRNAs
increased collagen IV compared to NS-siRNA treatment
(Figure 4B).
We immunoprecipitated (IP) collagen IV from both SMG
lysates and the culture media (data not shown) using a Col4a2
monoclonal antibody and detected Col4a1, Col4a2, and the
NC1 domains by Western blot with a polyclonal antibody to
collagen IV. Both purified collagen IV and recombinant NC1
domains were used as positive controls. We observed an
increase in the intact Col4a1 and Col4a2 with MT1-, MT2-, and
MT3-siRNA compared to NS-siRNA, although MT2-siRNA had
the greatest increase (upper blot in Figure 4C). Also, the NC1
domains decreased after both MT1- and MT2-siRNA, compared
to the NS-siRNA (lower blot in Figure 4C). There was a decrease
in NC1 domains released in GM6001- or TIMP2-treated E12
SMGs (Figures S6A and S6B). We were unable to distinguish
between a1(IV)NC1 and a2(IV)NC1, as their molecular weights
(25 kDA) are similar, and the polyclonal antibody recognizes
both of them (Figure S6B). Taken together, these findings indi-
cate that decreasing epithelial MT2 expression decreases
epithelial cell proliferation, increases intracellular collagen IV486 Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevaccumulation, and decreases proteolytic release of NC1
domains.
Collagen IV NC1 Domains Restore Branching
Morphogenesis after MT2-siRNA Treatment
by Increasing Epithelial Cell Proliferation
and MT2 Expression via b1 Integrin Signaling
NC1 domains, released by proteolysis of collagen IV chains,
bind to integrin receptors and inhibit angiogenesis (Mundel and
Kalluri, 2007; Ortega and Werb, 2002). We added recombinant
a1(IV)NC1 and a2(IV)NC1 domains to SMGs treated with MT2-
siRNA. The NC1 domains increased epithelial branching and
MT2 expression (Figure 5A), increased cell proliferation, and
decreased collagen IV accumulation in the epithelium (Fig-
ure 5B). NC1 domains also rescued epithelial morphogenesis
after MT1-siRNA treatment in E12 SMG culture (Figures S7A
and S7B). Finally, we isolated endogenous NC1 domains by IP
directly from E13 SMGs, and these also rescued branching
morphogenesis after MT2-siRNA treatment (Figure S8), showing
that both the endogenous and recombinant NC1 domains have
similar activity.
In order to determine how the NC1 domains regulate protease
or BM synthesis and epithelial proliferation, we analyzed the
expression of MMPs and BM components 4 hr after treatment
of E13 SMGs with NC1 domains (Figure 5C). MT1, MT2, MT3,
and Col4a2 were all upregulated, whereas Col4a1 did not
change. We also measured expression of proproliferative genes
involved in SMG morphogenesis such as FGFR (Hoffman et al.,
2002; Steinberg et al., 2005) and EGFR (Kashimata et al., 2000;
Koyama et al., 2008) signaling components. Fgfr1b, Fgfr2b,
Fgf1, andHbegf increasedwith 4 hr of NC1 treatment (Figure 5C),
whereas Egfr, ErbB2, and ErbB3 increased 24 hr after NC1 treat-
ment (data not shown), downstream of the early transcriptionalier Inc.
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MT2-MMP and Collagen-IV in SMG Morphogenesischanges. We then used the induction of MT2 expression by
NC1 domains as an assay to investigate the receptors and
downstream signaling from NC1 domains.
Integrins are receptors for NC1 domains, and their down-
stream signaling pathways likely regulate the NC1-dependent
MT2 transcription. Function-blocking b1 integrin antibodies
also inhibit SMG branching morphogenesis (Rebustini et al.,
2007). Therefore, we coincubated function-blocking antibodies
against a1, a2, a5, aV, and b1 integrins and the NC1 domains
for 4 hr with SMGs (Figure 5D) and measured MT2 expression.
There was a significant decrease in MT2 expression, with a1,
a2, and b1 integrin antibodies, whereas a5 or aV antibodies
(data not shown) did not decrease MT2 expression. Both AKT
and MAPK signaling pathways are critical for SMG morphogen-
esis (Larsen et al., 2003), and the NC1 domains increased
phosphorylation of AKT but not MAPK (Figures 5E and 5F). We
Figure 4. MT2-siRNA Decreases Epithelial
Proliferation, Increases Intracellular Colla-
gen IV, andReducesCollagen IV Proteolysis
with Less Release of NC1 Domains
(A) Proliferation decreases after MT2-siRNA treat-
ment. The whole-mount Ki67 immunostaining in
the left-hand panels are a single projection. MT2-
siRNA increases intracellular collagen IV staining
in the epithelium (E, arrows) and mesenchyme
(M, arrowheads) in the middle panels. Images are
single 2 mM confocal sections.
(B) Quantification of fluorescent staining shows
a significant decrease of cell proliferation (Ki67)
in the epithelium after MT2-siRNA treatment, and
all siRNAs increase total collagen IV staining
compared to the NS-siRNA. The collagen IV poly-
clonal antibody detects the intact chains, NC1
domains, and other collagen IV proteolytic frag-
ments. Staining was normalized to perlecan,
another basement membrane component. One-
way ANOVA, *p < 0.05 and ***p < 0.001. Error
bars represent ± SD.
(C) IP-WB detection of the intact Col4a1 and
Col4a2 chains (upper blot) and the NC1 domains
(lower blot) from siRNA-treated SMGs (20 mg of
SMG lysate for each IP) shows an accumulation
of collagen IV full-length chains and a decrease
in the NC1 domains after MT2-siRNA treatment.
Recombinant NC1 domains were used as positive
controls (see Figures S6 and S8). MT1- and
MT3-siRNAs increase intact collagen IV but to a
lesser extent than MT2-siRNA.
also measured a decrease in both AKT
and MAPK signaling after MT2-siRNA
treatment (Figures 5E and 5F), although
other factors may influence downstream
signaling at 36 hr. Inhibitors of PI3 kinase
(LY294002) and MAPK (UO126) also
inhibited NC1-dependent MT2 expres-
sion (Figure 5G). The a1(IV)NC1-depen-
dent MT2 expression decreased with
LY294002 but not UO126, whereas
a2(IV)NC1-dependent MT2 expression
decreased with both inhibitors (Fig-
ure 5G). Together, these results show that recombinant
a1(IV)NC1 and a2(IV)NC1 domains influence epithelial prolifera-
tion and morphogenesis via a1/a2b1 integrin signaling, AKT
phosphorylation, and downstream MT-MMP, Hbegf, and
FGF-related gene expression.
HBEGF Increases Collagen IV NC1 Domain Release,
Which Rescues MT-siRNA-Treated SMGs and
Increases Both MT-MMP and Hbegf Expression
Although NC1 domains upregulate both Hbegf and Fgf1 expres-
sion (Figure 5C), only exogenous HBEGF rescues MT2-siRNA
effects on branching morphogenesis (Figures 6A and 6B), while
FGF1 does not (data not shown). We added either HBEGF or
recMT2 catalytic domains after MT1- and MT2-siRNA treat-
ments and observed both a rescue of morphogenesis and an
increase in the release of NC1 domains (Figures 6A–6C). TheDevelopmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevier Inc. 487
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MT2-MMP and Collagen-IV in SMG MorphogenesisFigure 5. Recombinant a1(IV)NC1 and
a2(IV)NC1 Domains Rescue Branching Mor-
phogenesis after MT2-siRNA Treatment by
Increasing Epithelial Cell Proliferation and
MT2 and Col4a2 via b1 Integrin Signaling
and AKT Phosphorylation
(A) SMGs were cultured with MT1- or MT2-siRNAs
and NC1 domains for 36 hr. The number of end
buds is in the upper graph, and qPCR analysis of
MT2expression is in the lowergraph.The reduction
inMT2 expression is restored by NC1 domains.
(B) The NC1 domains decrease the intracellular
collagen IV accumulation and increase prolifera-
tion to control levels (Ki67 staining). Quantification
of the fluorescent staining is shown on the right
panel graphs.
(C) The NC1 domains were incubated with control
SMGs for 4 hr, which increases MT1, MT2, MT3,
Col4a2, Hbegf, and FGF signaling-related genes
as measured by qPCR.
(D) The increase of MT2, after 4 hr of treatment
with NC1 domains, was reduced by coincubating
with function-blocking a1, a2, and b1 integrin anti-
bodies but not by control IgG or function-blocking
aV or a5 antibodies (data not shown). qPCR
analysis of MT2 is shown.
(E)a1(IV)NC1and a2(IV)NC1 activate AKT (2.7- and
6.7-fold above control, respectively), which is in-
hibited by a PI3 kinase inhibitor (LY294002) but
not a MAPK inhibitor (UO126). SMGs were incu-
bated with LY294002 (25 mM, 30 min) prior to NC1
treatment (2 mg/mL, 1 hr). AKT phosphorylation
also decreases after 36 hr of MT2-siRNA treatment
compared with the NS-siRNA. Western blot anal-
ysis in the lower graph shows the ratio of p-AKT/
total AKT (expressed as fold change of control).
(F) a1(IV)NC1 and a2(IV)NC1 do not activate MAPK above control levels and UO126 (20 mM, 30min) reducesMAPK phosphorylation. MAPK phosphorylation also
decreases after 36 hr of MT2-siRNA treatment compared with the NS-siRNA. The identical blot from (E) was analyzed, and the graph shows the ratio of p-MAPK/
total MAPK (number of pixels, AU 3 103).
(G) a1(IV)NC1- and a2(IV)NC1-domain-dependentMT2 expression decreases to control levels with LY294002 treatment. The graph showsMT2 qPCR 4 hr after
inhibitor treatments. a1(IV)NC1-inducedMT2 expression was also decreased by UO126 treatments. One-way ANOVA for (A), (B), and (D), Student’s t test for (C);
*p < 0.05; **p < 0.01; and ***p < 0.001. Error bars represent ± SD.HBEGF-mediated release of NC1 domains may in part be due to
the further increase in MT-MMP expression, and these data
suggest MT1 and MT2 may function in a similar manner. In addi-
tion, exogenous HBEGF increases epithelial proliferation and
morphogenesis, while increasing MT2, MT3, and endogenous
Hbegf expression in the epithelium (Figures 6D and 6E).
Together, these results connect the proteolytic release of NC1
domains from collagen IV with the induction of more protease
expression and EGFR signaling.
DISCUSSION
Here, we propose amechanism to integrate the dynamic balance
between proteolysis and proliferation during SMG branching
morphogenesis. MT2-MMP-dependent release of bioactive
collagen IV NC1 domains, which signal via b1 integrins and AKT
activation, influences collagen IV synthesis and increases
MT-MMP, FGFR, andHbegf expression, which stimulate epithe-
lial proliferation (Figure 7). Additionally, HBEGF further increases
MT2 expression and upregulates its own production, providing
further stimulus for rapid branchingmorphogenesis during devel-488 Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevopment. The physiological functions ofMT2 in vivo have not been
described, but cancer cell lines overexpressing MT-MMPs show
they have similar proteolytic functions (Hotary et al., 2000, 2006).
A significant finding here, with broad relevance to the interpreta-
tion of genetic models, is the transcriptional compensation
observed between MT1, MT2, and MT3, with TIMP2 treatment,
siRNA knockdown, and in vivo, in both the MT1 heterozygous
and null SMGs (Figure 1D). Together, these data suggest that
the amount of protease activity and MT-MMP gene dosage is
critical.
Proteolysis is required for SMG branching morphogenesis,
and GM6001 caused a profound inhibition of branching without
upregulating MT-MMP expression but reducing the amount of
NC1 domains released (Figure 1A and Figure S6). GM6001
inhibits both ADAMs and MMPs, and ADAM10 and ADAM17
activate pro-HBEGF, which signals via EGFR (Sanderson et al.,
2006), and all these components are present in the SMG (Fig-
ure S2). In our experiments, GM6001 likely inhibits HBEGF acti-
vation, although this is not directly investigated here. However,
GM6001-treated SMGs are not rescued by exogenous NC1
domains (data not shown), suggesting that proteolysis is stillier Inc.
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MT2-MMP and Collagen-IV in SMG MorphogenesisFigure 6. HBEGF and recMT2 Rescue Branching Morphogenesis after MT-siRNA Treatment by Increasing Collagen IV NC1 Domains,
Epithelial Proliferation, and MT2 and Hbegf Expression
(A) SMGs cultured with MT1- or MT2-siRNAs and HB-EGF (10 ng/ml) or recMT2 (0.05 mg/mL) for 36 hr.
(B) HB-EGF and recMT2 rescue branching morphogenesis after both MT1- and MT2-siRNA treatment. ANOVA *p < 0.05, and ***p < 0.001.
(C) The reduction of NC1 domains with MT1- and MT2-siRNA was restored with HBEGF or recMT2 treatment. SMG lysates were analyzed by IP-WB for NC1
domains after 36 hr as described in the Experimental Procedures.
(D) Epithelial proliferation was detected by whole-mount Ki67 staining (green; left panels are a single projection of a confocal stack). Higher magnification of the
end buds (right panels) shows that intracellular collagen IV (red), which increaseswithMT2-siRNA treatment, decreases with HBEGF treatment. Images are single
2 mm confocal sections.
(E) HBEGF (1 ng/ml) rescues FGF10-dependent epithelial morphogenesis after MT2-siRNA treatment. There is a significant decrease in the morphogenic index
(number of end buds 3 the length of the ducts, insert graph) with MT2-siRNA, which is restored with HBEGF treatment. HB-EGF increases the expression of
epithelial MT2 and the Hbegf to control levels and decreases Col4a2 to its basal level, in SMG epithelium treated with MT2-siRNA. qPCR is shown in the lower
graph. One-way ANOVA, *p < 0.05; **p < 0.01; and ***p < 0.001. Error bars represent ± SD.Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevier Inc. 489
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MT2-MMP and Collagen-IV in SMG Morphogenesisrequired downstream of NC1 treatment to rescue morphogen-
esis. Additionally, HBEGF does not completely rescue branching
morphogenesis after GM6001 treatment, although additional
clefts occur but the end buds do not enlarge (data not shown).
However, HBEGF does restore branching after MT1- or MT2-
siRNA treatment. Exogenous HBEGF increases Hbegf, MT2,
and MT3 expression (Figure 6E), and more NC1 domains are
released (Figure 6C), which would feed back to further increase
Hbegf and MT-MMP expression (Figure 5C). HBEGF is ex-
pressed in the SMG epithelium (Figure 6E) and was previously
shown to induce some epithelial cleft formation after MMP
inhibition (Umeda et al., 2001). Our data suggest that the addition
of either HBEGF or NC1 domains to siRNA-treated SMGs
requires downstream protease activity to completely rescue
branching morphogenesis. Together, our experiments suggest
that branching morphogenesis requires the proteolytic release
of NC1 domains in concert with activation of HBEGF.
Genetically modified mice that are HBEGF/ die postnatally
from cardiac hypertrophy and have poorly differentiated
lungs, but SMG branching morphogenesis was not analyzed
during early development (Jackson et al., 2003). However, the
EGFR/ mice have reduced MT1 and Mmp2 expression
(Kajanne et al., 2007) and hypoplastic SMGs (Jaskoll and
Melnick, 1999). There may also be functional redundancy and/
or compensation occurring with EGF ligands and/or receptors
in these single knockout mice. We conclude that the regulation
of MT-dependent collagen IV proteolysis and HBEGF/EGFR
signaling in the SMG are closely interconnected and control
epithelial proliferation and branching morphogenesis.
We demonstrate the presence of collagen IV NC1 domains
directly in developing tissue, and the NC1 domains isolated
from the SMG have a similar bioactivity as recombinant NC1
domains in SMG explant culture (Figure S8). We could also IP
the NC1 domains from the SMG culture media (data not shown).
Fewer NC1 domains were immunoprecipitated after siRNA
knockdown (Figure 4C) of both MT1 and MT2, suggesting that
they both release NC1 domains, although epithelial MT2 is
more critical at this early stage ofmorphogenesis. Integrin recep-
Figure 7. Working Model Showing How
MT2-Dependent Release of Bioactive
Collagen IV NC1 Domains Regulates
Protease Expression and Proliferation
during SMG Branching Morphogenesis
Epithelial MT2-mediated proteolysis of collagen IV
releases NC1 domains that signal via b1 integrins
and downstream AKT activation to increase MT2
and Col4a2, as well as epithelial proliferation via
both FGFR and HBEGF-mediated mechanisms.
HBEGF further increases MT2 expression and
upregulates endogenous Hbegf, providing further
stimulus for rapid SMGbranchingmorphogenesis.
tors bind a1, a2, and a3 (IV)NC1 domains
and mediate distinct biological effects
(Mundel and Kalluri, 2007; Ortega and
Werb, 2002). Collagen a3(IV)NC1 (Ped-
chenko et al., 2004) and a2(IV)NC1 (He
et al., 2004) promote endothelial cell
adhesion and inhibit proliferation via avb3 and avb5 integrins,
and a1(IV)NC1 suppresses tumor growth and induces apoptosis
in endothelial cells via a1b1 (Colorado et al., 2000) and a2b1 in-
tegrins (Ortega and Werb, 2002). To address how NC1 domains
might signal in the SMG, we coincubated either function-block-
ing anti-integrin antibodies or chemical inhibitors of signaling
pathways with NC1 domains and show that NC1 domains signal
via b1-integrin and PI3K-AKT to induce MT2 expression.
However, our experiments do not show direct binding of the
NC1 domains to any individual integrin subunits, and it is
possible that the integrin antibodies might exert indirect effects
on integrin binding to ECM independent from NC1 domain
binding to the cell surface. Surprisingly, our data suggest some
differences downstream of a1(IV)NC1 and a2(IV)NC1 binding,
although further analysis of integrin binding and signaling is
required. We propose that NC1 domains signal via b1 integrins
and restore epithelial proliferation in MT2-siRNA-treated SMGs
by the early induction of epithelial HBEGF and FGF1, thus
increasing EGF and FGF signaling (Figure 5C). Others have
shown that MT2 is upregulated during epithelial cell proliferation
in a trophoblast cell line treated with TNFa (Hiden et al., 2007)
and during the preinvasive to invasive transition in a model of
breast cancer cell invasion (Rizki et al., 2008).
Another important finding is the increased Col4a2 transcrip-
tion when MT-MMP function is reduced (Figures 1, 3, and 4).
The Col4a2 chain directs triple helix assembly (Khoshnoodi
et al., 2006); therefore, our findings suggest that positive feed-
back from NC1 domain signaling may influence collagen IV
assembly or secretion. Col4a2 can also be secreted as a mono-
mer that binds proMMP9 on the cell surface (Olson et al., 1998),
and this may occur when MT2 decreases, although this remains
to be investigated. Collagen IV also binds BMP4 (Wang et al.,
2008), which antagonizes FGF signaling during SMG branching
morphogenesis (Hoffman et al., 2002). Whether collagen IV
NC1 domains influence the bioavailability of BMP4 in SMGs
remains to be determined.
Both MT2-siRNA and GM6001 increased the intracellular
accumulation of collagen IV but did not increase the490 Developmental Cell 17, 482–493, October 20, 2009 ª2009 Elsevier Inc.
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MT2-MMP and Collagen-IV in SMG Morphogenesiscolocalization of collagen IV in lysosomes (Figure S5). Collagen
turnover involves pericellular collagenases, MT1-MMP, and
intracellular uPARAP, and the genetic deletion of both results
in postnatal lethality (Wagenaar-Miller et al., 2007). Extracellular
collagenolysis followed by uPARAP-dependent endocytic
uptake and lysosomal delivery occurs in mesenchymal cells
(Kjoller et al., 2004; Madsen et al., 2007). The epithelial accumu-
lation of collagen IV suggests that MT2-dependent proteolysis
may occur before transit into lysosomes, although other epithe-
lial-specific mechanisms of collagen IV degradation may occur.
The catalytic domains of MT-MMPs (recMTs) have been used
to investigate substrate specificities (d’Ortho et al., 1997). Here,
we demonstrate that recMT2 and recMT3 rescue SMGmorpho-
genesis after MT2-siRNA treatment, but surprisingly recMT1
does not (Figure S4A). All three recMTs release NC1 domains
from collagen IV in vitro, from both immunoprecipitated SMG
collagen IV and bovine lens basement membrane (Figures S4D
and S4E). Therefore, our data suggest that in the ex vivo SMG
assay other factors influence recMT1 activity. A possible expla-
nation for the differences between in vitro and ex vivo results is
that exogenous recMT1 may mimic the overexpression of MT1,
which others have shown causes autocatalytic shedding of
MT1, leaving inactive MT1 on the cell surface that can bind
collagen IV, inhibiting its degradation (Tamet al., 2002). However,
this type of autocatalytic shedding has not been described for
MT2 or MT3. Alternatively, there may be cofactors in the SMG
that selectively enhance recMT2 and recMT3 activity compared
to recMT1.
This report shows that epithelial MT2 influences collagen IV
metabolismandepithelial proliferationduringbranchingmorpho-
genesis. Our studies provide mechanistic insight into how
collagen IV NC1 domains provide transcriptional feedback to
increase MT-MMP, collagen IV, and proproliferative gene
expression via b1-integrin signaling, influencing collagen IV
proteolysis and synthesis during branching morphogenesis.
The proteolytic release of NC1 domains is a critical component
providing transcriptional feedback to control MT-MMP and
Hbegf expression, thus integrating collagen IV metabolism with
epithelial proliferation.
EXPERIMENTAL PROCEDURES
Ex Vivo Mouse SMG Explant Cultures
Explant culture of intact E12 (a single end bud) and E13 (three to five end buds)
ICR mouse SMGs and MT1/ null SMGs (Holmbeck et al., 1999) has been
previously described (Patel et al., 2008; Steinberg et al., 2005). SMGs were
cultured on polycarbonate filters in microwell dishes (MatTek, MA) containing
DMEM/F12 supplemented with 100 U/ml of penicillin, 100 mg/ml of strepto-
mycin, 150 mg/ml of vitamin C, and 50 mg/ml of transferrin. Epithelia were
cultured in laminin-111 (Trevigen, MD). Both rhFGF10 and rhHBEGF were
used (R&D Systems, MN).
Inhibitors, Recombinant TIMPs, Antibodies, and Rescue
Experiments Using Recombinant NC1 Domains and MT-MMPs
GM6001 (5–20 mM, Chemicon, CA) was added to the culture media and
compared to a DMSO control. Recombinant TIMPs 1 and 2 (2 mg/ml, Triple
Point Biologics, OR) or heat-inactivated TIMPs were added to the culture
media for 24–36 hr. A function-blocking antibody targeting MT1 (AB8102,
Chemicon, CA) and IgG controls were used at 4 mg/ml. The purification of re-
combinant human NC1 domains of collagen IV has been previously described
(Sado et al., 1998). The recombinant catalytic domains of MT1, MT2, and MT3Develop(0.05–1 mg/ml, Calbiochem, CA) or heat-inactivated controls were added to
culture media. Preservative-free function-blocking anti-b1 integrin (Ha2/5),
anti-a1 (Ha31/8), anti-a5 (5H10-27), anti-aV (H9.2B8), and hamster IgG
(BD Biosciences, CA), and anti-a2b1 (BMA2.1) integrin and rat IgG (both
Millipore, MA) were also used. LY294002 and UO126 were used at 25 and
20 mM, respectively (Calbiochem, CA).
Real-Time PCR
RNA was purified using RNAqueous and DNase reagents (Ambion, TX)
and cDNA prepared using SuperScript reagents (BioRad, CA). SYBR-
green qPCR was performed using 1 ng of cDNA, with primers designed by
Beacon Designer software (sequences available on request). Melt-curves
and primer efficiency were determined as previously described (Rebustini
et al., 2007). Gene expressionwas normalized toS29 and to the corresponding
experimental control, and reactions were run in triplicate and repeated three
times.
Whole-Mount Immunofluorescence
Whole-mount staining of SMGshas beenpreviously described (Rebustini et al.,
2007). Primary antibodies included rabbit anti-mouse MT1, MT2, and MT3
(Triple Point Biologics, OR), rat anti-mouse perlecan, goat or rabbit anti-mouse
collagen IV (bothChemicon, CA), and rat anti-mouse syndecan 1 (BDPharMin-
gen, CA). Nuclei were stained with TO-PRO-3 (Invitrogen, CA), and images
were obtained using a Zeiss LSM 510 confocal microscope.
Gelatin Zymography
The conditioned media were concentrated and analyzed using gelatin zymog-
raphy in 10% gels, according to the manufacturer’s specifications (Invitrogen,
CA). The volume of media in each lane was normalized to either the total
protein or RNA from the SMGs.
RNA Interference
RNA interference was performed using at least three different siRNAs for each
MT1-, MT2-, and MT3-MMP (Dharmacon, CA); a nonsilencing scrambled
siRNA sequence: AATTCTCCGAACGTGTCACGT; and RNAiFect reagent
(QIAGEN, CA). The siRNA sequences used in the figures were TGAGGGTTTC
CACGGCGACAGTAC (for MT1-MMP knockdown), GACCTTCTCCAGCACT
GACCTG (for MT2-MMP knockdown), and TGATGGACCAACAGACCGAGA
TAAAGAAGG (for MT3-MMP knockdown). Transfection and analysis of
knockdown by qPCR and quantitative immunofluorescent analysis have
been previously described (Rebustini et al., 2007).
Immunoprecipitation and Western Blot
A mouse anti-Col4a2 Mab (Chemicon, CA) was used to IP the collagen IV
chains (Col4a1 and Col4a2) and the corresponding noncollagenous NC1
domains (a1 NC1 and a2 NC1) from SMGs lysed in RIPA buffer. The immune
complexes were captured using Protein-G sepharose and diluted in NuPAGE
LDSsample buffer (Invitrogen,CA) forWestern blot analysis.Collagen IV chains
and the NC1 domains were detected with a polyclonal rabbit anti-collagen IV
using purified collagen IV, a1(IV)NC1, and a2(IV)NC1 domains as positive
controls. Phospho- and total AKT and MAPK antibodies (Cell Signaling, CA)
were also used.
Branching Morphogenesis, Morphometric Analysis, and Statistics
Branchingmorphogenesiswasmeasuredby counting the number of endbuds,
whereas epithelial morphogenesiswas calculated bymultiplying the number of
end buds by the length of the ducts as previously reported (Patel et al., 2008).
All SMG data were obtained using at least five SMGs/group and repeated at
least three times. Data were analyzed for statistical significance using the t
test to compare two different groups and one-way ANOVA to compare more
than two experimental groups. All graphs show the mean ± SD.
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